The impact of antibiotics and proton pump inhibitors in neoadjuvant treatment of HER2+breast cancer

被引：0
|
作者：
Martins, J. B. [1 ]
Santos, J. [2 ]
Mendonca, J. C. [1 ]
Barbosa, A. R. [1 ]
Lima, B. F. [1 ]
Carvalho, C. T. [1 ]
Teixeira, A. [1 ]
Coutinho, C. [1 ]
机构：
[1] Hosp Senhora da Oliveira, Med Oncol Dept, Guimaraes, Portugal
[2] Univ Minho, Sch Med, Braga, Portugal
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 08期
关键词：
D O I：
10.1016/j.annonc.2022.09.047
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
46P
引用
收藏
页码：S1397 / S1398
页数：2
相关论文
共 50 条
  • [1] Loss of HER2 and disease prognosis after neoadjuvant treatment of HER2+breast cancer
    Branco, Francisco P.
    Machado, Duarte
    Silva, Filipa F.
    Andre, Saudade
    Catarino, Ana
    Madureira, Rosa
    Pinto, Joao M.
    Godinho, Joao P.
    Simoes, Pedro D.
    Brito, Margarida
    Casa-Nova, Mafalda
    Moreira, Antbnio R.
    Passos-Coelho, Jose L.
    [J]. AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2019, 11 (09): : 6110 - 6116
  • [2] HER2+breast cancer
    Hicks, David G.
    Kulkarni, Swati
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 129 (02) : 263 - 273
  • [3] Dual HER2 Blockade in Neoadjuvant Treatment of HER2+Breast Cancer: A Meta-Analysis and Review
    Wang, Chaokun
    Chen, Jing
    Xu, Xiangyun
    Hu, Xiaochen
    Kong, Dejiu
    Liang, Gaofeng
    Wang, Xinshuai
    [J]. TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2020, 19
  • [4] Treatment of ER+/HER2+breast cancer
    Johnston, Stephen
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [5] Adjuvant and neoadjuvant trastuzumab in combination with vinorelbine for HER2+breast cancer.
    Esfahani, Khashayar
    Ferrario, Cristiano
    Le, Philippe
    Panasci, Lawrence C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] The Pathological Response of Her2+Breast Cancer with Neoadjuvant Chemotherapy and Radiation Therapy
    Chao, M.
    Baker, C.
    Jassal, S.
    Law, M.
    Bevington, E.
    Stoney, D.
    Zantuck, N.
    Chew, G.
    Loh, S. W.
    Hyett, A.
    Guerrieri, M.
    Ng, M.
    Cokelek, M.
    Neoh, D.
    Yong, C.
    Ho, H.
    Tacey, M.
    Joon, D. Lim
    Khor, R.
    Foroudi, F.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E17 - E17
  • [7] COST-ESTIMATE OF ADDING NEOADJUVANT PERTUZUMAB FOR THE TREATMENT OF HER2+BREAST CANCER IN AN INSTITUTION IN PORTUGAL
    Borges, A.
    Pereira, F.
    Redondo, P.
    Antunes, L.
    Vieira, C.
    Antunes, P.
    Bento, M. J.
    Sousa, S.
    Machado Lopes, J.
    Goncalves, F. R.
    Abreu de Sousa, J.
    Pereira, D.
    Borges, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S475 - S475
  • [8] Genomics of HER2+breast cancer
    Perou, C.
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [9] HER2+breast cancer treatment and cardiotoxicity: monitoring and management
    Jerusalem, Guy
    Lancellotti, Patrizio
    Kim, Sung-Bae
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2019, 177 (02) : 237 - 250
  • [10] Incidence and prognostic impact of HER2-positivity loss after dual HER2-directed neoadjuvant therapy for HER2+breast cancer
    LeVee, Alexis
    Spector, Kellie
    Larkin, Brigid
    Dezem, Felipe
    Plummer, Jasmine
    Dadmanesh, Farnaz
    Patil, Sujata
    McArthur, Heather L. L.
    [J]. CANCER MEDICINE, 2023, 12 (09): : 10647 - 10659
12345